GlassScriptPhysician profile
Eleonor Quan
NPI 1770502254
$5,370.43
in general payments reported to CMS, 2019-2025
47 companies · $19.04 in 2025
The $19.04 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,371 · 2020: $1,912 · 2023: $68.88 · 2025: $19.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $70.15 · Education: $17.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $70.15 |
| Education | $17.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $507.97 | 2019-2020 | |
| Amgen INC. | $408.30 | 2019-2020 | |
| Janssen Biotech, INC. | $381.52 | 2019-2023 | Imbruvica |
| Astrazeneca Pharmaceuticals LP | $308.98 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $299.29 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $292.00 | 2019-2020 | |
| Genentech USA, INC. | $285.83 | 2019-2020 | |
| Genzyme Corporation | $267.40 | 2019-2020 | |
| Pfizer INC. | $242.12 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $180.46 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $149.61 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $123.11 | 2019-2020 | |
| Aurobindo Pharma USA, INC. | $122.06 | 2019-2020 | |
| Incyte Corporation | $111.30 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.76 | 2019 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eleonor Quan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.